Ewha Med J.  2023 Dec;46(S1):e27. 10.12771/emj.2023.e27.

Advances in the Treatment of Colorectal Cancer with Peritoneal Metastases: A Focus on Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy

• Jeon Y
• Park EJ

• KMID: 2550847
• DOI: http://doi.org/10.12771/emj.2023.e27

Abstract

In stage IV colorectal cancer (CRC), peritoneal metastasis is associated with a poor prognosis. Hyperthermic intraperitoneal chemotherapy (HIPEC) after cytoreductive surgery (CRS) is an effective treatment option that offers survival benefits in patients with peritoneal metastatic CRC. For over the past several decades, a multitude of studies have been conducted on CRS and HIPEC for peritoneal metastatic diseases, and research in this area is ongoing. Proper patient selection and a meticulous preoperative assessment are crucial for achieving successful postoperative outcomes. The completeness of cytoreduction and the surgical techniques employed are key factors in improving oncologic outcomes following CRS and HIPEC. The role of HIPEC for both therapeutic and prophylactic purposes is currently being evaluated in recent clinical trials. This article reviews the fundamental principles of CRS combined with HIPEC and discusses recent clinical trials concerning the treatment of CRS and HIPEC in CRC patients with peritoneal carcinomatosis.

Keyword

Colorectal neoplasms; Peritoneal neoplasms; Hyperthermic intraperitoneal chemotherapy; Cytoreduction surgical procedures; Hyperthermic intraperitoneal chemotherapy (HIPEC)

Figure

• 

  Fig. 1. Hyperthermic intraperitoneal chemotherapy methods. (A) Open technique, (B) closed technique.

Reference

References

1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015; 136(5):E359–E386. DOI: 10.1002/ijc.29210. PMID: 25220842.

2. Verwaal VJ, Van Ruth S, De Bree E, Van Slooten GW, Van Tinteren H, Boot H, et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol. 2003; 21(20):3737–3743. DOI: 10.1200/JCO.2003.04.187. PMID: 14551293.

3. Kim YJ, Kim CH. Treatment for peritoneal metastasis of patients with colorectal cancer. Ann Coloproctol. 2021; 37(6):425–433. DOI: 10.3393/ac.2021.00920.0131. PMID: 34961304. PMCID: PMC8717073.

4. Varela C, Kim NK. Surgical treatment of low-lying rectal cancer: updates. Ann Coloproctol. 2021; 37(6):395–424. DOI: 10.3393/ac.2021.00927.0132. PMID: 34961303. PMCID: PMC8717072.

5. Piozzi GN, Kim SH. Robotic intersphincteric resection for low rectal cancer: technical controversies and a systematic review on the perioperative, oncological, and functional outcomes. Ann Coloproctol. 2021; 37(6):351–367. DOI: 10.3393/ac.2021.00836.0119. PMID: 34784706. PMCID: PMC8717069.

6. Purkayastha J, Singh PR, Talukdar A, Das G, Yadav J, Bannoth S. Feasibility and outcomes of multivisceral resection in locally advanced colorectal cancer: experience of a tertiary cancer center in North-East India. Ann Coloproctol. 2021; 37(3):174–178. DOI: 10.3393/ac.2020.06.03. PMID: 34111348. PMCID: PMC8273713.

7. Kim MC, Oh JH. Lateral pelvic lymph node dissection after neoadjuvant chemoradiotherapy in patients with rectal cancer: a single-center experience and literature review. Ann Coloproctol. 2021; 37(6):382–394. DOI: 10.3393/ac.2021.00913.0130. PMID: 34961302. PMCID: PMC8717070.

8. Mahendran B, Balasubramanya S, Sebastiani S, Smolarek S. Extended lymphadenectomy in locally advanced rectal cancers: a systematic review. Ann Coloproctol. 2022; 38(1):3–12. DOI: 10.3393/ac.2021.00703.0100. PMID: 34788526. PMCID: PMC8898625.

9. Torky R, Alessa M, Kim HS, Sakr A, Zakarneh E, Sauri F, et al. Characteristics of patients presented with metastases during or after completion of chemoradiation therapy for locally advanced rectal cancer: a case series. Ann Coloproctol. 2021; 37(3):186–191. DOI: 10.3393/ac.2020.08.10.1. PMID: 32972094. PMCID: PMC8273715.

10. Segelman J, Granath F, Holm T, Machado M, Mahteme H, Martling A. Incidence, prevalence and risk factors for peritoneal carcinomatosis from colorectal cancer. Br J Surg. 2012; 99(5):699–705. DOI: 10.1002/bjs.8679. PMID: 22287157.

11. Franko J, Shi Q, Goldman CD, Pockaj BA, Nelson GD, Goldberg RM, et al. Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841. J Clin Oncol. 2012; 30(3):263–267. DOI: 10.1200/JCO.2011.37.1039. PMID: 22162570. PMCID: PMC3269953.

12. Klaver YLB, Lemmens VEPP, Nienhuijs SW, Luyer MDP, de Hingh IHJT. Peritoneal carcinomatosis of colorectal origin: incidence, prognosis and treatment options. World J Gastroenterol. 2012; 18(39):5489–5494. DOI: 10.3748/wjg.v18.i39.5489. PMID: 23112540. PMCID: PMC3482634.

13. Lee Y, Park I, Cho H, Gwak G, Yang K, Bae BN. Effect of adjuvant chemotherapy on elderly stage II high-risk colorectal cancer patients. Ann Coloproctol. 2021; 37(5):298–305. DOI: 10.3393/ac.2020.00829.0118. PMID: 34228912. PMCID: PMC8566145.

14. Au J, Hulme-Moir FM, Herd A, Kozman MA. Extensive resection for treatment of locally advanced primary mucinous adenocarcinoma arising from fistula-in-ano. Ann Coloproctol. 2021; 37((Suppl 1)):S7–S10. DOI: 10.3393/ac.2019.11.19. PMID: 32054254. PMCID: PMC8359692.

15. Franko J, Shi Q, Meyers JP, Maughan TS, Adams RA, Seymour MT, et al. Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database. Lancet Oncol. 2016; 17(12):1709–1719. DOI: 10.1016/S1470-2045(16)30500-9. PMID: 27743922.

16. Sugarbaker PH. Successful management of microscopic residual disease in large bowel cancer. Cancer Chemother Pharmacol. 1999; 43((Suppl 1)):S15–S25. DOI: 10.1007/s002800051093. PMID: 10357554.

17. Jacquet P, Sugarbaker PH. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Cancer Treat Res. 1996; 82:359–374. DOI: 10.1007/978-1-4613-1247-5_23. PMID: 8849962.

18. Elias D, Gilly F, Boutitie F, Quenet F, Bereder JM, Mansvelt B, et al. Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study. J Clin Oncol. 2010; 28(1):63–68. DOI: 10.1200/JCO.2009.23.9285. PMID: 19917863.

19. Chua TC, Esquivel J, Pelz JOW, Morris DL. Summary of current therapeutic options for peritoneal metastases from colorectal cancer. J Surg Oncol. 2013; 107(6):566–573. DOI: 10.1002/jso.23189. PMID: 22688776.

20. Chua TC, Morris DL, Esquivel J. Impact of the peritoneal surface disease severity score on survival in patients with colorectal cancer peritoneal carcinomatosis undergoing complete cytoreduction and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol. 2010; 17(5):1330–1336. DOI: 10.1245/s10434-009-0866-x. PMID: 20033321.

21. Pelz JOW, Stojadinovic A, Nissan A, Hohenberger W, Esquivel J. Evaluation of a peritoneal surface disease severity score in patients with colon cancer with peritoneal carcinomatosis. J Surg Oncol. 2009; 99(1):9–15. DOI: 10.1002/jso.21169. PMID: 18937291.

22. Glehen O, Kwiatkowski F, Sugarbaker PH, Elias D, Levine EA, De Simone M, et al. Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study. J Clin Oncol. 2004; 22(16):3284–3292. DOI: 10.1200/JCO.2004.10.012. PMID: 15310771.

23. Elias D, Mariani A, Cloutier AS, Blot F, Goéré D, Dumont F, et al. Modified selection criteria for complete cytoreductive surgery plus HIPEC based on peritoneal cancer index and small bowel involvement for peritoneal carcinomatosis of colorectal origin. Eur J Surg Oncol. 2014; 40(11):1467–1473. DOI: 10.1016/j.ejso.2014.06.006. PMID: 25086990.

24. Kwakman R, Schrama AM, Van Olmen JP, Otten RH, de Lange-de Klerk ES, De Cuba EM, et al. Clinicopathological parameters in patient selection for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal cancer metastases: a meta-analysis. Ann Surg. 2016; 263(6):1102–1111. DOI: 10.1097/SLA.0000000000001593. PMID: 26756756.

25. Tabrizian P, Jibara G, Shrager B, Franssen B, Yang MJ, Sarpel U, et al. Outcomes for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the elderly. Surg Oncol. 2013; 22(3):184–189. DOI: 10.1016/j.suronc.2013.06.001. PMID: 23827047.

26. Votanopoulos KI, Newman NA, Russell G, Ihemelandu C, Shen P, Stewart JH, et al. Outcomes of cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) in patients older than 70 years; survival benefit at considerable morbidity and mortality. Ann Surg Oncol. 2013; 20(11):3497–3503. DOI: 10.1245/s10434-013-3053-z. PMID: 23780382. PMCID: PMC3881978.

27. López-López V, Cascales-Campos PA, Schneider MA, Gil J, Gil E, Gomez-Hidalgo NR, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in elderly patients. A systematic literature review. Surg Oncol. 2016; 25(4):378–384. DOI: 10.1016/j.suronc.2016.09.002. PMID: 27916169.

28. Sugarbaker PH. Peritonectomy procedures. Ann Surg. 1995; 221(1):29–42. DOI: 10.1097/00000658-199501000-00004. PMID: 7826158. PMCID: PMC1234492.

29. Dodson RM, Kuncewitch M, Votanopoulos KI, Shen P, Levine EA. Techniques for cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol. 2018; 25(8):2152–2158. DOI: 10.1245/s10434-018-6336-6. PMID: 29388121.

30. Park SY, Choi GS, Park JS, Kim HJ, Ryuk JP, Yun SH, et al. Laparoscopic cytoreductive surgery and early postoperative intraperitoneal chemotherapy for patients with colorectal cancer peritoneal carcinomatosis: initial results from a single center. Surg Endosc. 2014; 28(5):1555–1562. DOI: 10.1007/s00464-013-3351-3. PMID: 24368743.

31. Lorimier G, Linot B, Paillocher N, Dupoiron D, Verrièle V, Wernert R, et al. Curative cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy in patients with peritoneal carcinomatosis and synchronous resectable liver metastases arising from colorectal cancer. Eur J Surg Oncol. 2017; 43(1):150–158. DOI: 10.1016/j.ejso.2016.09.010. PMID: 27839895.

32. Baratti D, Kusamura S, Iusco D, Cotsoglou C, Guaglio M, Battaglia L, et al. Should a history of extraperitoneal disease be a contraindication to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal cancer peritoneal metastases? Dis Colon Rectum. 2018; 61(9):1026–1034. DOI: 10.1097/DCR.0000000000001156. PMID: 30086051.

33. Fujiwara K, Armstrong D, Morgan M, Markman M. Principles and practice of intraperitoneal chemotherapy for ovarian cancer. Int J Gynecol Cancer. 2007; 17(1):1–20. DOI: 10.1111/j.1525-1438.2007.00809.x. PMID: 17291226.

34. Park EJ, Ahn J, Gwak SW, Park KS, Baik SH, Hwang SJ. Pharmacologic properties of the carrier solutions for hyperthermic intraperitoneal chemotherapy: comparative analyses between water and lipid carrier solutions in the rat model. Ann Surg Oncol. 2018; 25(11):3185–3192. DOI: 10.1245/s10434-018-6628-x. PMID: 30027459. PMCID: PMC6132421.

35. Sticca RP, Dach BW. Rationale for hyperthermia with intraoperative intraperitoneal chemotherapy agents. Surg Oncol Clin N Am. 2003; 12(3):689–701. DOI: 10.1016/S1055-3207(03)00029-2. PMID: 14567025.

36. Murono K, Kawai K, Hata K, Emoto S, Kaneko M, Sasaki K, et al. Regimens of intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal cancer. Anticancer Res. 2018; 38(1):15–22. DOI: 10.21873/anticanres.12186.

37. van Eden WJ, Kok NFM, Woensdregt K, Huitema ADR, Boot H, Aalbers AGJ. Safety of intraperitoneal mitomycin C versus intraperitoneal oxaliplatin in patients with peritoneal carcinomatosis of colorectal cancer undergoing cytoreductive surgery and HIPEC. Eur J Surg Oncol. 2018; 44(2):220–227. DOI: 10.1016/j.ejso.2017.10.216. PMID: 29258720.

38. Rodriguez Silva C, Moreno Ruiz FJ, Bellido Estévez I, Carrasco Campos J, Titos García A, Ruiz López M, et al. Are there intra-operative hemodynamic differences between the Coliseum and closed HIPEC techniques in the treatment of peritoneal metastasis? A retrospective cohort study. World J Surg Oncol. 2017; 15(1):51. DOI: 10.1186/s12957-017-1119-2. PMID: 28222738. PMCID: PMC5320712.

39. Yan TD, Black D, Savady R, Sugarbaker PH. Systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal carcinoma. J Clin Oncol. 2006; 24(24):4011–4019. DOI: 10.1200/JCO.2006.07.1142. PMID: 16921055.

40. Lambert LA, Armstrong TS, Lee JJ, Liu S, Katz MHG, Eng C, et al. Incidence, risk factors, and impact of severe neutropenia after hyperthermic intraperitoneal mitomycin C. Ann Surg Oncol. 2009; 16(8):2181–2187. DOI: 10.1245/s10434-009-0523-4. PMID: 19475451. PMCID: PMC2711905.

41. Quénet F, Elias D, Roca L, Goéré D, Ghouti L, Pocard M, et al. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2021; 22(2):256–266. DOI: 10.1016/S1470-2045(20)30599-4. PMID: 33476595.

42. Franko J, Shi Q, Meyers JP, Maughan TS, Adams RA, Seymour MT, et al. Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database. Lancet Oncol. 2016; 17(12):1709–1719. DOI: 10.1016/S1470-2045(16)30500-9. PMID: 27743922.

43. Park KJ. Against all odds: why surgeons need to be more aggressive in the era of the multidisciplinary team approach to colorectal cancer. Ann Coloproctol. 2022; 38(6):393–397. DOI: 10.3393/ac.2022.00822.0117. PMID: 36596299. PMCID: PMC9816559.

44. Delhorme JB, Sattler L, Severac F, Triki E, Gross I, Romain B, et al. Prognostic factors of hemorrhagic complications after oxaliplatin-based hyperthermic intraperitoneal chemotherapy: toward routine preoperative dosage of Von Willebrand factor? Eur J Surg Oncol. 2017; 43(6):1095–1101. DOI: 10.1016/j.ejso.2017.01.015. PMID: 28209329.

45. van De Vlasakker VCJ, Lurvink RJ, Cashin PH, Ceelen W, Deraco M, Goéré D, et al. The impact of PRODIGE 7 on the current worldwide practice of CRS-HIPEC for colorectal peritoneal metastases: a web-based survey and 2021 statement by Peritoneal Surface Oncology Group International (PSOGI). Eur J Surg Oncol. 2021; 47(11):2888–2892. DOI: 10.1016/j.ejso.2021.05.023. PMID: 34020808.

46. Goéré D, Glehen O, Quenet F, Guilloit JM, Bereder JM, Lorimier G, et al. Second-look surgery plus hyperthermic intraperitoneal chemotherapy versus surveillance in patients at high risk of developing colorectal peritoneal metastases (PROPHYLOCHIP–PRODIGE 15): a randomised, phase 3 study. Lancet Oncol. 2020; 21(9):1147–1154. DOI: 10.1016/S1470-2045(20)30322-3. PMID: 32717180.

47. Klaver CEL, Wisselink DD, Punt CJA, Snaebjornsson P, Crezee J, Aalbers AGJ, et al. Adjuvant hyperthermic intraperitoneal chemotherapy in patients with locally advanced colon cancer (COLOPEC): a multicentre, open-label, randomised trial. Lancet Gastroenterol Hepatol. 2019; 4(10):761–770. DOI: 10.1016/S2468-1253(19)30239-0. PMID: 31371228.

48. Arjona-Sánchez A, Espinosa-Redondo E, Gutiérrez-Calvo A, Segura-Sampedro JJ, Pérez-Viejo E, Concepción-Martín V, et al. Efficacy and safety of intraoperative hyperthermic intraperitoneal chemotherapy for locally advanced colon cancer: a phase 3 randomized clinical trial. JAMA Surg. 2023; 158(7):683–691. DOI: 10.1001/jamasurg.2023.0662. PMID: 37099280.